Brief: Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI
22/06/2026 12:42
BRIEF-Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI June 22 (Reuters) - Regenxbio Inc Spokesperson:
REGENXBIO: WE ALIGNED WITH FDA REGARDING NEXT STEPS NEEDED FOR POTENTIAL ACCELERATED APPROVAL OF NAVSUNLI - SPOKESPERSON
REGENXBIO INC: EXPECTS TYPE A MEETING TO TAKE PLACE IN JULY AND TO RESUBMIT THE BLA RAPIDLY FOLLOWING THE MEETING IN Q3 2026-SPOKESPERSON
Further company coverage: RGNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics